045 – Gilead PrEP Revenue in JEOPARDY!

Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN.

I mention a short-term trade idea but remember to do your own due diligence and do not consider this investment advice.


032 – GILD Fails Phase 3 in NASH!

On this episode, I talk about results from the Gilead Phase 3 NASH trial that announced no improvement in patients treated with Selonsertib (ASK1 inhibitor). I also talk about the DBVT BLA resubmission and a hot hot Q319 trading idea on CBIO.

Relevant links:

*this is not investment advice, only my opinion and ideas*


#biotech #breakingbiotech #nash

%d bloggers like this: